Delivery Agile Solutions For Your Autoimmune Trials

Autoimmune Disease

Advance your treatment with a team focused on the right sites and the best outcomes for patients.

Partner with experienced experts that help overcome challenges and optimize your delivery.

Apply our wealth of data to meet the needs of sites and patients throughout your autoimmune clinical trial.

Get complete support for your autoimmune indications.

Advance your autoimmune clinical trial across the spectrum of development—from integrated Phase I-III protocol designs and programs to Phase IV observational study design and execution. We offer decades of experience and expertise to drive the entire process while also considering the changing global regulatory environment.

As an agile partner, we understand you’re working to achieve more specific and personalized treatment for patients, especially for patients with autoimmune diseases. We’re here to help advance precision medicines and enable more early interventions by fully supporting the delivery of your clinical trial.

Experience matters when choosing a partner.

Let's Connect

We’ve been honored to serve as a CRO partner of choice for our biotech and pharmaceutical customers as we’ve advanced their autoimmune programs. In the last 5 years, we have supported:

265

Autoimmune Studies

9,096

Sites

33,903명

환자

Top Indications

류마티스 관절염
Systemic Lupus Erythematosuse
Crohn’s Disease
Osteoarthritis
Psoriasis
Ulcerative Colitis
Ankylosing Spondylitis

Applying powerful data to optimize your autoimmune trial.

To support on-time and on-budget study conduct, we take a data-driven approach to your clinical plan design. We use real-time de-identified laboratory data, from central labs global investigator performance data*, a patient intelligence database and technologies to transform data into unique insights. (*Fortrea will maintain exclusive CRO access to the Labcorp data that supports its clinical-enabling solutions for a fixed period of time.)

We can determine the most realistic and credible investigator performance assessment based upon sites’ past performance and deliver higher performance in country selection, optimize patient recruitment and enable more accurate forecasting when compared with others in the industry.

Together, we are pushing science and data forward in ways that are truly designed for and inspired by patients.

Get to know us

Learn about our autoimmune subject matter experts and their role in advancing your trial.

Michael George Vice President and Global Head

Maixing Ai, MD Senior Medical Director

Andrea Buschiazzo, MD, MBA Senior Medical Director

Chris Kemp, PhD Executive Director and Global Lead, Strategic Delivery & Growth

AnneMarie DiGiacomo Associate Director, Strategy Delivery & Growth

Meet the team

Get the latest updates from our autoimmune disease team

We’re sharing our latest news, events and publications.

White Paper

Phase 1 trials in autoimmune disease review

Read the white paper

White Paper

Systemic Lupus Erythematosus assessment and endpoint review

Read the white paper

Incorporating the voice of the patient

We’re here to deliver life-changing solutions, faster, and help your products reach the patients that need the most. We incorporate a wealth of existing patient insights gathered from survey responses within our Patient Intelligence Library, which spans a number of indications, including Rheumatoid Arthritis, Crohn's Disease, Gout, Osteoarthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

With this proprietary information, we can identify key factors, such as the largest barrier to join a trial, willingness to wear a mobile device outside of the standard clinical trial visits, preferred travel times to participate in a trial and interest in study visits at home. Combining these insights with our early engagement, feasibility and site selection, we can enable a site- and patient-centric approach that enhances retention and streamlines your study delivery.